Ameluz® is to be approved for further skin diseases in the coming years as well as in other parts of the world.

Clinical trials must be conducted for further indications to be approved. Which trials are conducted for which new indications is a matter determined in close coordination with the respective regulator.

In the near future, Biofrontera is aiming for the US approval of Ameluz® for superficial basal cell carcinoma, acne, as well as new indications for actinic keratosis for areas beyond the face and scalp.

The active principle of Ameluz® enables the application of the medication in various further indications, for which the company is developing specific strategies.